Pseudomonas aeruginosa OMP Specific Neutra™ Antibody Products

Are you struggling with extended drug discovery timelines, ineffective antibiotic candidates, or challenges in targeting Pseudomonas aeruginosa's antibiotic-resistant mechanisms? Creative Biolabs' P. aeruginosa OMP-specific Neutra™ antibody products leverage advanced recombinant antibody engineering and high-throughput epitope mapping to deliver precision tools for neutralizing outer membrane proteins (OMPs), accelerating therapeutic development against multidrug-resistant infections.

Introduction to P. aeruginosa OMP

Pseudomonas aeruginosa, a gram-negative opportunistic pathogen, expresses outer membrane proteins (OMPs) as key virulence factors enabling host colonization, immune evasion, and antibiotic resistance. P. aeruginosa OMPs are structurally conserved, β-barrel transmembrane proteins integral to nutrient uptake, biofilm formation, and efflux pump assembly. These proteins are pivotal for bacterial survival in hostile environments, including the human respiratory tract, burn wounds, and immunocompromised tissues.

Fig.1 Key virulence factors of P. aeruginosa infections.¹

• Basic Information

P. aeruginosa OMPs comprise a diverse family of porins, adhesins, and efflux channels. Notably, OprF, the most abundant OMP, stabilizes the outer membrane structure and regulates bacterial motility. OprD facilitates carbapenem uptake, while OprM functions as an essential component of multidrug efflux pumps. Due to their surface exposure and critical roles in pathogenicity, OMPs are prime targets for antibody-mediated neutralization.

• Structural Insights

OMPs adopt a β-barrel fold with extracellular loops conferring ligand specificity. For example, OprF's N-terminal domain anchors the protein to the peptidoglycan layer, while its C-terminal β-barrel forms a hydrophilic pore. OprM's trimeric structure, coupled with proton motive force, drives antibiotic efflux. Structural plasticity in extracellular loops enables immune evasion but also provides accessible epitopes for neutralizing antibodies.

• Related Signaling Pathways

P. aeruginosa OMPs activate host innate immune responses via Toll-like receptor 4 (TLR4) and TLR2, triggering NF-κB and MAPK pathways to induce pro-inflammatory cytokines. Paradoxically, hyperactivation of these pathways contributes to tissue damage in chronic infections. Neutralizing OMPs can reduce excessive inflammation while enhancing bacterial clearance.

• Associated Pathologies

P. aeruginosa causes life-threatening infections in cystic fibrosis, ventilator-associated pneumonia, burn wounds, and immunocompromised patients. Its multidrug resistance, mediated by OMP-linked efflux systems and biofilm formation, complicates treatment. Over 30% of hospital-acquired P. aeruginosa infections exhibit carbapenem resistance, underscoring the urgent need for novel therapeutics.

Applications of P. aeruginosa OMP-Specific Neutralizing Antibodies

• Therapeutic Development Against Resistant Infections

Neutralizing antibodies targeting OprM or OprD restore antibiotic susceptibility by blocking efflux or porin-mediated uptake. In preclinical models, antibody-antibiotic conjugates reduced bacterial load in lung infections by 90%, demonstrating potential for combination therapies in cystic fibrosis.

• Rapid Diagnostic Tools

OMP-specific antibodies enable rapid detection of P. aeruginosa in clinical samples via lateral flow assays, reducing diagnosis time from days to hours. This supports timely therapeutic decisions in sepsis or pneumonia cases.

• Vaccine Adjuvants

Antibodies targeting OprF elicit protective immunity in animal models, reducing mortality in acute infection scenarios. Epitope-mapped antibodies guide vaccine design by identifying immunodominant regions.

• Biofilm Disruption

Antibodies against biofilm-associated OMPs destabilize extracellular matrices, sensitizing bacteria to phagocytosis and antimicrobial peptides.

Targeting OMPs with Neutralizing Antibodies

Creative Biolabs offers P. aeruginosa OMP-specific Neutra™ antibody products that combine cutting-edge engineering with rigorous validation for precision antimicrobial research. Available in multiple formats (IgG, Fab, scFv) and scalable for clinical development, these antibodies are your gateway to overcoming multidrug resistance. Our OMP-specific antibodies are engineered to inhibit virulence functions:

- High-affinity binding to extracellular loops disrupts porin function, reducing antibiotic efflux.

- Inhibition of biofilm-associated OMPs (e.g., OprF) weakens bacterial adhesion and biofilm stability.

- Opsonization enhances macrophage-mediated phagocytosis.

Validated in functional assays, these antibodies exhibit cross-strain reactivity and synergize with traditional antibiotics to overcome resistance.

Contact us today to discuss your project requirements.

REFERENCE

1. Killough, Matthew, Aoife Maria Rodgers, and Rebecca Jo Ingram. "Pseudomonas aeruginosa: Recent advances in vaccine development." Vaccines 10.7 (2022): 1100. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/vaccines10071100